LifeStance Health Group (LFST) Expected to Announce Earnings on Thursday

Key Points

• Q1 2026 earnings due before the market opens on Thursday, May 7 at 8:30 AM ET, with analysts forecasting EPS of $0.01 and revenue of $387.43 million.
• The board authorized a $100 million share repurchase (about 3.6% of outstanding shares), a move the company says signals the board believes the stock may be undervalued.
• Insiders have sold a total of 4,389,939 shares (~$30.8M) in the last 90 days; the stock trades near $7.43 with a market cap of $2.88B, a PE of ~372, and an average analyst price target of $9.83 (consensus: Buy).

LifeStance Health Group (NASDAQ:LFST - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect LifeStance Health Group to post earnings of $0.01 per share and revenue of $387.4320 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.The company had revenue of $382.20 million for the quarter, compared to analysts' expectations of $378.51 million. During the same quarter in the prior year, the company earned ($0.01) EPS. The firm's quarterly revenue was up 17.4% on a year-over-year basis. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Trading Down 3.1%

Shares of NASDAQ:LFST opened at $7.43 on Thursday. The company has a market capitalization of $2.88 billion, a PE ratio of 371.69 and a beta of 1.13. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. The business's fifty day simple moving average is $6.75 and its 200-day simple moving average is $6.60. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.09.

LifeStance Health Group announced that its board has authorized a share repurchase plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Insider Buying and Selling

In other LifeStance Health Group news, Director Robert Bessler sold 62,147 shares of the firm's stock in a transaction on Friday, April 24th. The shares were sold at an average price of $7.05, for a total value of $438,136.35. Following the completion of the transaction, the director owned 1,274,448 shares of the company's stock, valued at approximately $8,984,858.40. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Darren M. Black sold 4,314,939 shares of LifeStance Health Group stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $7.01, for a total transaction of $30,247,722.39. Following the sale, the director owned 29,209,776 shares of the company's stock, valued at $204,760,529.76. The trade was a 12.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 4,389,939 shares of company stock worth $30,775,881 in the last 90 days. 6.60% of the stock is currently owned by company insiders.

Institutional Trading of LifeStance Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock valued at $26,363,000 after purchasing an additional 1,839,465 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company's stock worth $45,998,000 after purchasing an additional 1,790,694 shares during the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of LifeStance Health Group by 100.0% during the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company's stock worth $21,120,000 after purchasing an additional 1,500,000 shares during the period. Barclays PLC lifted its holdings in shares of LifeStance Health Group by 74.7% during the third quarter. Barclays PLC now owns 3,508,552 shares of the company's stock worth $19,297,000 after purchasing an additional 1,499,687 shares during the period. Finally, Marshall Wace LLP purchased a new stake in LifeStance Health Group in the third quarter valued at approximately $7,637,000. Institutional investors and hedge funds own 85.50% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LFST shares. Jefferies Financial Group raised shares of LifeStance Health Group to a "strong-buy" rating in a research report on Thursday, March 12th. Weiss Ratings upgraded LifeStance Health Group from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 27th. Canaccord Genuity Group raised their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Barclays upped their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, March 6th. Finally, Wall Street Zen upgraded LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Sunday, February 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $9.83.

About LifeStance Health Group

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.